Sirt1 Activation Prevents High Glucose-induced Angiotensin Converting Enzyme 2 Downregulation in Renal Tubular Cells by Regulating the TIMP3/ADAM17 Pathway

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2024 Jan 6

PMID 38183511

Authors

Ziyu Guo

Qingyu Niu

Xinning Mi

Bing Yang

Meishun Cai

Yaoxian Liang

Affiliations

Soon will be listed here.

Abstract

Background: Angiotensin converting enzyme 2 (ACE2) exerts renoprotective effects in diabetic kidney disease (DKD) by converting angiotensin (Ang) II into Ang (1-7). Previous studies have demonstrated that ACE2 expression in renal tubules is downregulated in DKD, but the mechanism is not fully understood. Sirtuin-1 (Sirt1) is a protein deacetylase that may regulate the activity of the renin-angiotensin system. The present study investigated the effects of Sirt1 on ACE2 expression under high glucose (HG) conditions and the underlying signaling pathway.

Methods And Results: Rats with DKD and NRK-52E cells cultured with HG were employed in this study. Western blotting, immunohistochemistry detection and qRT-PCR were performed for protein and mRNA expression analyses. Rats subjected to DKD displayed downregulated expression of Sirt1 and ACE2 in kidneys. Resveratrol, an activator of Sirt1, restored ACE2 expression and ameliorated renal injuries. Similarly, pharmacological activation of Sirt1 with SRT1720 markedly upregulated ACE2 in NRK-52E cells cultured with HG, while Sirt1 small interfering RNA (siRNA) further suppressed ACE2 expression. In addition, A disintegrin and metalloproteinase (ADAM) 17 was observed to be upregulated, and its inhibitor, tissue inhibitor of metalloproteinase 3 (TIMP3), was downregulated in the kidneys of diabetic rats and NRK-52E cells incubated with HG. The TIMP3/ADAM17 pathway was involved in the regulation of ACE2 expression, as evidenced by decreased ACE2 expression levels after TIMP3-siRNA pretreatment. SRT1720 ameliorated the imbalance of TIMP3/ADAM17 induced by HG and consequently enhanced the expression of ACE2. Notably, the above effect of SRT1720 on ACE2 was interrupted by TIMP3-siRNA.

Conclusions: Our findings suggest that Sirt1 activation may prevent HG-induced downregulation of renal tubular ACE2 by modulating the TIMP3/ADAM17 pathway. Sirt1 stimulation might be a potential strategy for the treatment of DKD.

Citing Articles

Novel insights into the central protective role of ACE2 in diabetic cardiomyopathy: from underlying signaling pathways to therapeutic perspectives.

Li X, Qu S Mol Cell Biochem. 2025; .

PMID: 39928210 DOI: 10.1007/s11010-024-05196-6.

HIV-1 Tat Protein and Cigarette Smoke Mediated ADAM17 Upregulation Can Lead to Impaired Mucociliary Clearance.

Panda K, Santiago M, Rahman M, Ghorai S, Black S, Rahman I Cells. 2024; 13(23).

PMID: 39682757 PMC: 11640087. DOI: 10.3390/cells13232009.

References

Petrazzuolo A, Sabiu G, Assi E, Maestroni A, Pastore I, Lunati M . Broadening horizons in mechanisms, management, and treatment of diabetic kidney disease. Pharmacol Res. 2023; 190:106710. DOI: 10.1016/j.phrs.2023.106710. View

Nomura H, Kuruppu S, Rajapakse N . Stimulation of Angiotensin Converting Enzyme 2: A Novel Treatment Strategy for Diabetic Nephropathy. Front Physiol. 2022; 12:813012. PMC: 8787214. DOI: 10.3389/fphys.2021.813012. View

Pan X, Xu D, Zhang H, Zhou W, Wang L, Cui X . Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med. 2020; 46(6):1114-1116. PMC: 7106051. DOI: 10.1007/s00134-020-06026-1. View

Reich H, Oudit G, Penninger J, Scholey J, Herzenberg A . Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 2008; 74(12):1610-6. DOI: 10.1038/ki.2008.497. View

Liang Y, Deng H, Bi S, Cui Z, A L, Zheng D . Urinary angiotensin converting enzyme 2 increases in patients with type 2 diabetic mellitus. Kidney Blood Press Res. 2015; 40(2):101-10. DOI: 10.1159/000368486. View

Gutta S, Grobe N, Kumbaji M, Osman H, Saklayen M, Li G . Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes. Am J Physiol Renal Physiol. 2018; 315(2):F263-F274. PMC: 6139527. DOI: 10.1152/ajprenal.00565.2017. View

Mizuiri S, Hemmi H, Arita M, Ohashi Y, Tanaka Y, Miyagi M . Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis. 2008; 51(4):613-23. DOI: 10.1053/j.ajkd.2007.11.022. View

Tikellis C, Johnston C, Forbes J, Burns W, Burrell L, Risvanis J . Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension. 2003; 41(3):392-7. DOI: 10.1161/01.HYP.0000060689.38912.CB. View

Wysocki J, Ye M, Soler M, Gurley S, Xiao H, Bernstein K . ACE and ACE2 activity in diabetic mice. Diabetes. 2006; 55(7):2132-9. DOI: 10.2337/db06-0033. View

10.

Ye M, Wysocki J, Naaz P, Salabat M, Lapointe M, Batlle D . Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination?. Hypertension. 2004; 43(5):1120-5. DOI: 10.1161/01.HYP.0000126192.27644.76. View

11.

Meyer-Schwesinger C, Seipold L, Saftig P . Ectodomain shedding by ADAM proteases as a central regulator in kidney physiology and disease. Biochim Biophys Acta Mol Cell Res. 2021; 1869(3):119165. DOI: 10.1016/j.bbamcr.2021.119165. View

12.

Palau V, Pascual J, Soler M, Riera M . Role of ADAM17 in kidney disease. Am J Physiol Renal Physiol. 2019; 317(2):F333-F342. DOI: 10.1152/ajprenal.00625.2018. View

13.

Zhu H, Wang J, Nie W, Armando I, Han F . ADAMs family in kidney physiology and pathology. EBioMedicine. 2021; 72:103628. PMC: 8517843. DOI: 10.1016/j.ebiom.2021.103628. View

14.

Salem E, Grobe N, Elased K . Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am J Physiol Renal Physiol. 2014; 306(6):F629-39. PMC: 3949038. DOI: 10.1152/ajprenal.00516.2013. View

15.

Riera M, Anguiano L, Clotet S, Roca-Ho H, Rebull M, Pascual J . Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria. Am J Physiol Renal Physiol. 2015; 310(6):F534-46. DOI: 10.1152/ajprenal.00082.2015. View

16.

Casagrande V, Federici M, Menghini R . TIMP3 involvement and potentiality in the diagnosis, prognosis and treatment of diabetic nephropathy. Acta Diabetol. 2021; 58(12):1587-1594. PMC: 8542557. DOI: 10.1007/s00592-021-01766-y. View

17.

Rossi C, Marzano V, Consalvo A, Zucchelli M, Mortera S, Casagrande V . Proteomic and metabolomic characterization of streptozotocin-induced diabetic nephropathy in TIMP3-deficient mice. Acta Diabetol. 2017; 55(2):121-129. DOI: 10.1007/s00592-017-1074-y. View

18.

Kumari A, Sodum N, Ravichandiran V, Kumar N . Role of SIRT-1 as a Target for Treatment and Prevention of Diabetic Nephropathy: A Review. Curr Mol Pharmacol. 2023; 16(8):811-831. DOI: 10.2174/1874467216666230109140134. View

19.

Wu L, Zhang Y, Ma X, Zhang N, Qin G . The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol Biol Rep. 2012; 39(9):9085-93. DOI: 10.1007/s11033-012-1780-z. View

20.

Cardellini M, Menghini R, Martelli E, Casagrande V, Marino A, Rizza S . TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes. 2009; 58(10):2396-401. PMC: 2750223. DOI: 10.2337/db09-0280. View